2019
DOI: 10.1161/strokeaha.118.023664
|View full text |Cite
|
Sign up to set email alerts
|

Description of a Novel Phosphodiesterase (PDE)-3 Inhibitor Protecting Mice From Ischemic Stroke Independent From Platelet Function

Abstract: Supplemental Digital Content is available in the text.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
22
0

Year Published

2019
2019
2024
2024

Publication Types

Select...
10

Relationship

1
9

Authors

Journals

citations
Cited by 29 publications
(22 citation statements)
references
References 45 publications
0
22
0
Order By: Relevance
“…In addition to the enhancement of PA signals of blood, other signals could be found in this area. We speculated that these signals might be due to the extravasation of EB dye caused by BBB damage in the brain after IS since EB dye has a high affinity to plasma albumin in blood and is often used to detect the openness of the BBB 36, 37.…”
Section: Resultsmentioning
confidence: 99%
“…In addition to the enhancement of PA signals of blood, other signals could be found in this area. We speculated that these signals might be due to the extravasation of EB dye caused by BBB damage in the brain after IS since EB dye has a high affinity to plasma albumin in blood and is often used to detect the openness of the BBB 36, 37.…”
Section: Resultsmentioning
confidence: 99%
“…Indeed, cilostazol an inhibitor of phosphodiesterase-3 (PDE3), which dampens platelet activity due to sustained levels of cyclic nucleotide monophosphate (cAMP and cGMP), has been shown to reduce recurrent strokes (114, 115). However, data from experimental studies argues that the protective effect of PDE3-inhibitors might be independent of platelet inhibition (116).…”
Section: Discussionmentioning
confidence: 99%
“…Finally, the use of substance V, a novel and only recently described PDE3 inhibitor, has also proven effective in reducing the volumes of heart attacks and in improving neurological outcomes after experimental cerebral ischemia, with modalities of action that appear to be independent from platelet function. Thus, the pharmaceutical inactivation of PDE3 could also represent a different therapeutic approach to combat ischemic stroke, by reducing blood-brain barrier damage, brain tissue inflammation and local cell death [ 65 ].…”
Section: Cyclic Nucleotide Pathway In Vascular Resistance Thrombomentioning
confidence: 99%